BioAge Labs reported cash from operations of -$19.26M and free cash flow of -$19.59M for the quarter ended Jun 2026, up 3.6% year over year. This cash flow statement covers 12 quarters of results from Sep 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||
| Net Income | -11.79M | -15.78M | -12.73M | -13.51M | -23.10M | -21.59M | -12.99M | -21.55M | -20.13M | -25.72M | -22.15M | -25.90M |
| Depreciation and Depletion | 0.04M | 0.03M | 0.05M | 0.04M | 0.05M | 0.04M | 0.06M | 0.05M | 0.07M | 0.06M | 0.07M | |
| Share-based Compensation | 0.76M | 0.77M | 0.85M | 1.56M | 5.25M | 2.72M | 7.97M | 8.05M | 8.11M | 2.72M | 9.29M | 9.15M |
| Gains from Investment Securities | 0.01M | 0.07M | 0.31M | -0.46M | -0.06M | 0.01M | 0.04M | 0.22M | 0.11M | 0.20M | ||
| Cash from Operations | -8.50M | -15.67M | -15.78M | -14.93M | -5.14M | -17.36M | -19.97M | -16.04M | -28.25M | -24.05M | -19.26M | |
| Depreciation, Depletion & Amortization | ||||||||||||
| Amortizatization of Intangibles | 0.31M | 0.56M | ||||||||||
| Depreciation & Amortization (CF)Depreciation & Amortization | 0.04M | 0.03M | 0.05M | 0.04M | 0.05M | 0.04M | 0.06M | 0.05M | 0.07M | 0.06M | 0.07M | |
| Change in Working Capital | ||||||||||||
| Change in Receivables | 0.36M | 0.24M | -0.09M | 0.25M | -0.06M | -0.08M | ||||||
| Change in Account Payables | 1.31M | 0.36M | -1.57M | 1.34M | -0.13M | 2.05M | -2.60M | 3.65M | -2.31M | 0.33M | 2.58M | |
| Change in Accured Expenses | 3.01M | -4.12M | -1.66M | 8.20M | 2.21M | -6.95M | 2.73M | -0.54M | 1.35M | -3.84M | 3.86M | |
| Other Working Capital Changes | -3.35M | 0.94M | 0.68M | 0.02M | 10.86M | 1.18M | -4.08M | -1.54M | -2.31M | 2.98M | 1.88M | |
| Investing Activities | ||||||||||||
| Capital Expenditures | 0.04M | 0.30M | 0.03M | 0.43M | 0.16M | 0.02M | 0.11M | 0.03M | 0.33M | |||
| Change in Acquisitions & Divestments | 8.50M | 25.75M | 26.00M | 33.49M | 39.59M | |||||||
| Cash from Investing Activities | -0.04M | -0.30M | -0.03M | -77.99M | -15.64M | 12.84M | -14.43M | -46.75M | -164.51M | |||
| Financing Activities | ||||||||||||
| Other financing activities | 0.00M | 1.27M | 182.87M | 27.62M | 0.04M | 0.67M | 1.71M | 1.47M | ||||
| Debt Issuance and Repayment | ||||||||||||
| Long-Term Debt Issuances | 1.50M | 1.50M | 1.50M | 1.50M | 1.50M | 1.50M | 1.50M | 1.50M | 1.50M | 0.50M | ||
| Change in Capital Stock | ||||||||||||
| Net Shares Issued and Repurchased | 3.17M | 2.77M | 2.96M | 1.60M | ||||||||
| Net Equity Issued and Repurchased | 170.00M | 17.16M | 124.31M | |||||||||
| Misc. | ||||||||||||
| Cash from Financing Activities | -1.01M | 168.00M | -2.39M | 190.68M | 24.90M | -1.50M | -1.50M | -1.54M | 16.01M | 123.72M | 15.97M | |
| Exchange Rate Effect | 0.02M | -0.02M | -0.06M | 0.14M | -0.01M | -0.05M | -0.01M | -0.02M | -0.03M | -0.01M | ||
| Change in Cash | -9.58M | 152.35M | -18.22M | 175.39M | 19.88M | -96.86M | -37.16M | -4.76M | -26.68M | 52.89M | -167.81M | |
| Free Cash Flow | -8.50M | -15.67M | -15.82M | -15.24M | -5.16M | -17.79M | -20.13M | -16.07M | -28.36M | -24.07M | -19.59M | |
| Net Cash Flow | -9.51M | 152.33M | -18.20M | 175.45M | 19.74M | -96.85M | -37.11M | -4.75M | -26.67M | 52.92M | -167.81M |